Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191304 | 1.00 | VCAM1 (0.53) | VCAM1ALDH1A1MAPTERN1PTGS2 | |
| SCHEMBL3970653 | 0.90 | VCAM1 (0.50) | VCAM1ALDH1A1MAPTERN1HPGD | |
| SCHEMBL4133735 | 0.90 | VCAM1 (0.50) | VCAM1ALDH1A1MAPTERN1HPGD | |
| SCHEMBL18649004 | 0.88 | VCAM1 (0.49) | VCAM1ALDH1A1MAPTERN1PTGS2 | |
| SCHEMBL3091095 | 0.85 | HCAR3 (0.58) | ALDH1A1MAPTPTGS2LMNA | |
| SCHEMBL192101 | 0.85 | HCAR3 (0.58) | ALDH1A1MAPTPTGS2LMNA | |
| SCHEMBL3348702 | 0.85 | VCAM1 (0.53) | VCAM1ALDH1A1MAPTERN1HPGD | |
| SCHEMBL3348706 | 0.85 | VCAM1 (0.53) | VCAM1ALDH1A1MAPTERN1HPGD | |
| SCHEMBL544066 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS2HPGDKMT2A | |
| SCHEMBL544067 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| CN-109153648-B | Benzazepine dicarboxamide compounds having tertiary amide functional group | 豪夫迈·罗氏有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3468963-B1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-109311851-B | Dihydro pyrimidinyl benzazepine carboxamide compounds | 豪夫迈·罗氏有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-109311854-B | Benzazepine dicarboxamide compounds having secondary amide functionality | 豪夫迈·罗氏有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-11046671-B2 | Dihydropyrimidinyl benzazepine carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020255038-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| CN-107295798-B | Benzazepine dicarboxamide compound | 豪夫迈·罗氏有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3464245-B1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-5332755-A | Leukotriene antagonists as antiinflammatory agents and antiallergens | BAYER AKTIENGESELLSCHAFT (DE) | 1994-07-26 | — | — | US | disclosed |
| US-5234942-A | Treating allergic pulmonary disorders, asthma | ICI AMERICAS INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5118700-A | Leukotriene antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
| EP-0242167-B1 | HETEROCYCLIC CARBOXAMIDES | ICI AMERICAS INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4997844-A | Compounds for the treatment of allergic or inflammatory diseases or shock conditions | ICI AMERICAS INC. (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0409027-A1 | Indole derivatives, process for their preparation and their use in pharmaceuticals | BAYER AG (DE) | 1991-01-23 | — | — | EP | disclosed |
| US-4898863-A | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4894386-A | ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1990-01-16 | — | — | US | disclosed |
| EP-0290145-A1 | Aliphatic carboxamides | ZENECA INC. (US) | 1988-11-09 | — | — | EP | disclosed |
| EP-0242167-A2 | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | VCAM1 4036/4885ALDH1A1 3714/4885MAPT 3629/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | VCAM1 1936/4885ALDH1A1 2220/4885MAPT 4151/4885 |
| US-11046671-B2 | Dihydropyrimidinyl benzazepine carboxamide compounds | TLR8, TLR1, TLR5 | VCAM1 1147/4885ALDH1A1 1894/4885MAPT 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.